SCYX News - Candlesense

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

(NASDAQ:SCYX) JERSEY CITY, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-tre...

Clinical trials

about 14 hours ago

SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025

JERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-res...

Conference

11 days ago

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

JERSEY CITY, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-res...

What are the potential risks or challenges highlighted in the corporate update that could affect future performance? How does the sentiment score of 20 influence market perception, and what does it imply about investor sentiment? Did the company provide any updates on market opportunities or competitive positioning for its lead products?

Earnings

22 days ago